Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.
Identifieur interne : 003103 ( Main/Exploration ); précédent : 003102; suivant : 003104Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.
Auteurs : RBID : pubmed:15012611English descriptors
- KwdEn :
- Adult, Aged, Biopsy, Fine-Needle, Carcinoma (pathology), Carcinoma (radionuclide imaging), Female, Fluorodeoxyglucose F18 (diagnostic use), Humans, Indium Radioisotopes (diagnostic use), Iodine Radioisotopes (diagnostic use), Male, Middle Aged, Octreotide (diagnostic use), Prospective Studies, Radionuclide Imaging (methods), Radiopharmaceuticals (diagnostic use), Receptors, Somatostatin (metabolism), Sensitivity and Specificity, Thyroglobulin (blood), Thyroid Neoplasms (pathology), Thyroid Neoplasms (radionuclide imaging), Tomography, Emission-Computed, Whole-Body Counting.
- MESH :
- chemical , blood : Thyroglobulin.
- chemical , diagnostic use : Fluorodeoxyglucose F18, Indium Radioisotopes, Iodine Radioisotopes, Octreotide, Radiopharmaceuticals.
- chemical , metabolism : Receptors, Somatostatin.
- methods : Radionuclide Imaging.
- pathology : Carcinoma, Thyroid Neoplasms.
- radionuclide imaging : Carcinoma, Thyroid Neoplasms.
- Adult, Aged, Biopsy, Fine-Needle, Female, Humans, Male, Middle Aged, Prospective Studies, Sensitivity and Specificity, Tomography, Emission-Computed, Whole-Body Counting.
Abstract
Somatostatin receptor scintigraphy (SRS) with (111)In-octreotide has been suggested as a potential tool for the detection of recurrent or metastatic differentiated thyroid cancer when no radioiodine uptake can be demonstrated in tumour sites. However, there is no consensus concerning the performance and clinical impact of this examination in such instances.
PubMed: 15012611
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.</title><author><name sortKey="Giammarile, Francesco" uniqKey="Giammarile F">Francesco Giammarile</name><affiliation wicri:level="1"><nlm:affiliation>Nuclear Medicine Department, Centre Leon Berard, Lyon, France. giammari@lyon.fnclcc.fr</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Nuclear Medicine Department, Centre Leon Berard, Lyon</wicri:regionArea><placeName><region type="région">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Houzard, Claire" uniqKey="Houzard C">Claire Houzard</name></author><author><name sortKey="Bournaud, Claire" uniqKey="Bournaud C">Claire Bournaud</name></author><author><name sortKey="Hafdi, Zakia" uniqKey="Hafdi Z">Zakia Hafdi</name></author><author><name sortKey="Sassolas, Genevieve" uniqKey="Sassolas G">Genevieve Sassolas</name></author><author><name sortKey="Borson Chazot, Francoise" uniqKey="Borson Chazot F">Francoise Borson-Chazot</name></author></titleStmt><publicationStmt><date when="2004">2004</date><idno type="RBID">pubmed:15012611</idno><idno type="pmid">15012611</idno><idno type="wicri:Area/Main/Corpus">003259</idno><idno type="wicri:Area/Main/Curation">003259</idno><idno type="wicri:Area/Main/Exploration">003103</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Biopsy, Fine-Needle</term><term>Carcinoma (pathology)</term><term>Carcinoma (radionuclide imaging)</term><term>Female</term><term>Fluorodeoxyglucose F18 (diagnostic use)</term><term>Humans</term><term>Indium Radioisotopes (diagnostic use)</term><term>Iodine Radioisotopes (diagnostic use)</term><term>Male</term><term>Middle Aged</term><term>Octreotide (diagnostic use)</term><term>Prospective Studies</term><term>Radionuclide Imaging (methods)</term><term>Radiopharmaceuticals (diagnostic use)</term><term>Receptors, Somatostatin (metabolism)</term><term>Sensitivity and Specificity</term><term>Thyroglobulin (blood)</term><term>Thyroid Neoplasms (pathology)</term><term>Thyroid Neoplasms (radionuclide imaging)</term><term>Tomography, Emission-Computed</term><term>Whole-Body Counting</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Thyroglobulin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Fluorodeoxyglucose F18</term><term>Indium Radioisotopes</term><term>Iodine Radioisotopes</term><term>Octreotide</term><term>Radiopharmaceuticals</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Somatostatin</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Radionuclide Imaging</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Carcinoma</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Carcinoma</term><term>Thyroid Neoplasms</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Biopsy, Fine-Needle</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prospective Studies</term><term>Sensitivity and Specificity</term><term>Tomography, Emission-Computed</term><term>Whole-Body Counting</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Somatostatin receptor scintigraphy (SRS) with (111)In-octreotide has been suggested as a potential tool for the detection of recurrent or metastatic differentiated thyroid cancer when no radioiodine uptake can be demonstrated in tumour sites. However, there is no consensus concerning the performance and clinical impact of this examination in such instances.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">15012611</PMID><DateCreated><Year>2004</Year><Month>03</Month><Day>11</Day></DateCreated><DateCompleted><Year>2004</Year><Month>05</Month><Day>04</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0804-4643</ISSN><JournalIssue CitedMedium="Print"><Volume>150</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Mar</Month></PubDate></JournalIssue><Title>European journal of endocrinology / European Federation of Endocrine Societies</Title><ISOAbbreviation>Eur. J. Endocrinol.</ISOAbbreviation></Journal><ArticleTitle>Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.</ArticleTitle><Pagination><MedlinePgn>277-83</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Somatostatin receptor scintigraphy (SRS) with (111)In-octreotide has been suggested as a potential tool for the detection of recurrent or metastatic differentiated thyroid cancer when no radioiodine uptake can be demonstrated in tumour sites. However, there is no consensus concerning the performance and clinical impact of this examination in such instances.</AbstractText><AbstractText Label="DESIGN AND METHODS" NlmCategory="METHODS">A prospective study was undertaken to evaluate SRS in 43 patients (18 men, 25 women) with papillary (n=20), follicular (n=9), insular (n=6) and oncocytic (n=8) thyroid carcinomas with elevated serum thyroglobulin (Tg) levels and no detected radioiodine uptake.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Evaluation criteria were interpreted in terms of an assumed presence of tumoural tissue. Sensitivity of SRS was 51%, clearly lower than that of conventional imaging procedures, and of positron emission tomography using [(18)F]-2-fluoro-2-deoxy-d-glucose, performed in a subset of 27 patients. In addition, we observed two false-positive foci of uptake of octreotide that corresponded to inflammatory pulmonary sites. The sensitivity was higher in patients with Tg levels greater than 50 microg/l (76%) for detecting mediastinal lesions (93%), and in patients with oncocytic cancer (88%). Finally, SRS changed treatment strategy in four patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In differentiated thyroid cancer, SRS is a moderately sensitive method for the detection of lesions unable to concentrate iodine and appears useful only in patients with very high Tg levels or in oncocytic cancer.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Giammarile</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><Affiliation>Nuclear Medicine Department, Centre Leon Berard, Lyon, France. giammari@lyon.fnclcc.fr</Affiliation></Author><Author ValidYN="Y"><LastName>Houzard</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Bournaud</LastName><ForeName>Claire</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hafdi</LastName><ForeName>Zakia</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Sassolas</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Borson-Chazot</LastName><ForeName>Francoise</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType>Comparative Study</PublicationType><PublicationType>Evaluation Studies</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Endocrinol</MedlineTA><NlmUniqueID>9423848</NlmUniqueID><ISSNLinking>0804-4643</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Indium Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Iodine Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radiopharmaceuticals</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Receptors, Somatostatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance>Fluorodeoxyglucose F18</NameOfSubstance></Chemical><Chemical><RegistryNumber>9010-34-8</RegistryNumber><NameOfSubstance>Thyroglobulin</NameOfSubstance></Chemical><Chemical><RegistryNumber>RWM8CCW8GP</RegistryNumber><NameOfSubstance>Octreotide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Biopsy, Fine-Needle</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Carcinoma</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Indium Radioisotopes</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Iodine Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Octreotide</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radionuclide Imaging</DescriptorName><QualifierName MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiopharmaceuticals</DescriptorName><QualifierName MajorTopicYN="Y">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Receptors, Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroglobulin</DescriptorName><QualifierName MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Thyroid Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Tomography, Emission-Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Whole-Body Counting</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>3</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>5</Month><Day>5</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>3</Month><Day>12</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15012611</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003103 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003103 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:15012611
|texte= Diagnostic management of suspected metastatic thyroid carcinoma: clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine scans.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:15012611" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |